Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Winship Cancer Institute, Emory University, Atlanta, GA, United States



Survival: 7.4 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
   
Drugs:
Country: United States
   
City/State/Province: Atlanta, GA
   
Hospital: Winship Cancer Institute, Emory University
   
Journal: Link
   
Date: 9/2012

Description:
Patients:
This phase 2 study involved advanced non-small-cell lung cancer patients who were divided into two separate treatment groups. Group A consisted of 94 patients with a median age of 60 years; 55 were male. Group B had 94 patients with a median age of 62 years; 56 were male.

Treatment:
Patients in group A were treated with the biologic therapy agent called dacomitinib, which is a tyrosine kinase inhibitor that interferes with tumor growth.

Patients in group B were treated with the biologic therapy agent called erlotinib, which is a tyrosine kinase inhibitor that interferes with tumor growth.

Toxicities:
Treatment-related death due to pneumonia was reported for group A. Grade 3 diarrhea and grade 1-3 skin disorders were also reported.

Treatment-related deaths due to pneumonia and pulmonary embolism were reported for group B. Grade 3 acne and diarrhea, and grade nausea and fatigue were also reported.

Results:
The median overall survival rates for groups A and B were 9.53 and 7.44 months, respectively.

Support:
This study was supported by the Pfizer pharmaceutical company.

Correspondence: Dr. Suresh S. Ramalingam; email: suresh.ramalingam@emory.edu

E-mail to a Friend Email Physician More Information